This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by 3P Solution.
This strategy included a 4-week lead-in period with DT (peginterferon plus ribavirin), followed by 32 weeks of TT with boceprevir or telaprevir, and then another 12 weeks of DT.
Reference
Camma C, et al. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. Journal of Hepatology : 23 May 2013. Available from: URL: http://dx.doi.org/10.1016/j.jhep.2013.05.019
Rights and permissions
About this article
Cite this article
Boceprevir/telaprevir worth its costs in CHC. PharmacoEcon Outcomes News 681, 8 (2013). https://doi.org/10.1007/s40274-013-0514-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0514-3